

EUROPEAN CANCER RESEARCH *Summit* *May 3, 2021* | PORTO, PORTUGAL

PRELIMINARY PROGRAM

08:30-09:00 - REGISTRATION

09:00-09:30 - WELCOME AND OPENING SESSION / REMARKS

Rui Henrique, *Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal*

Julio E. Celis, *Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark*

Marta Temido, *Minister for Health, Portugal*

Stella Kyriakides, *European Commissioner for Health and Food Safety, European Union*

Manuel Heitor, *Minister for Science, Technology and Higher Education, Portugal*

Mariya Gabriel, *European Commissioner for Innovation, Research, Culture, Education & Youth, European Union*

09:30-09:50 - PRESENTATION OF "PORTO DECLARATION ON CANCER RESEARCH" AND KEY NOTE SPEECHES:

Anton Berns, *President of the EACS: Infrastructures to sustain the EU cancer mission, Brussels, Belgium*

Walter Ricciardi, *President, EU Cancer Mission Board, Brussels, Belgium*

09:50-10:10 - COFFEE BREAK

10:10-12:10 - SESSION 1. INFRASTRUCTURE FOR TRANSLATIONAL RESEARCH

Chair: Ulrik Ringborg, *Cancer Center Karolinska, Stockholm, Sweden*

Presentations:

> **Basic/preclinical research: Generating proof of concept clinical trials is the engine for translational cancer research** | **Alexander Eggermont**, *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands*

> **The Comprehensive Cancer Centre: An essential infrastructure component** | **Simon Oberst**, *Cancer Research UK, Cambridge Center, Cambridge, UK*

> **Molecular and digital pathology is essential to develop personalized/precision cancer medicine** | **Fátima Carneiro**, *University of Porto, Porto, Portugal*

> **Immunotherapy: An expanding treatment modality** | **Laurence Zitvogel**, *Gustave Roussy Cancer Campus, Grand Paris, France*

> **Liquid biopsies: Expanding diagnostic procedures for both therapeutics and prevention** | **Olli Kallioniemi**, *Science for Life Laboratory, Stockholm, Sweden*

> **Acquisition of clinical and biological data: Implementation of computational sciences (Artificial Intelligence)** | **Jan Korbel**, *European Molecular Biology Laboratory, Heidelberg, Germany*

> **EC Knowledge Centre on Cancer** | **Guy Van den Eede**, *European Commission, Brussels, Belgium*

Debate (to be confirmed):

- > **Douglas Hanahan**, *École polytechnique fédérale de Lausanne - EPFL, Lausanne, Switzerland*
- > **Stefan Fröhling**, *National Center for Tumour Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany*
- > **Péter Nagy**, *National Institute of Oncology, Budapest, Hungary*
- > **Ken Mastris**, *President of European Cancer Patient Coalition (ECPC), Brussels, Belgium*
- > **Raquel Seruca**, *Institute for Investigation and Innovation in Health (i3S), Porto, Portugal*

12:10-12:50 - Lunch

12:50-14:40 - SESSION 2. INFRASTRUCTURE FOR CLINICAL AND PREVENTION TRIALS

Chair: **Josep Tabernero**, *Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain*

Presentations:

- > **Quality assurance of clinical trials structures: harmonisation of technical requirements to support multinational institutional collaborations in next-generation clinical trials** | **Denis Lacombe**, *European Organisation for Research and Treatment of Cancer, Brussels, Belgium*
- > **Molecular pathology for patient stratification in multicentre clinical trials** | **Paolo Nuciforo**, *Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain*
- > **Genomics: From discovery to bench-side genomics** | **Emile Voest**, *The Netherlands Cancer Institute, Amsterdam, The Netherlands*
- > **Modern Imaging in Oncology** | **Regina Beets-Tan**, *The Netherlands Cancer Institute, Amsterdam, The Netherlands*
- > **Repeated biopsies (fine needle aspiration and liquid biopsies), biobanking and clinical trials registries with clinical and biological information** | **Benjamin Besse**, *Institute Gustave-Roussy, Grand Paris, France*
- > **Development of innovative radiotherapy trials** | **Vincenzo Valentini**, *Policlinico Gemelli, Rome, Italy*
- > **Coordination of clinical trials activities from proof-of-concept trials to practice-changing clinical trials: added value compared to present treatments** | **Elena Garralda**, *Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain*
- > **New concepts and opportunities in cancer prevention clinical trials** | **Elisabete Weiderpass**, *International Agency for Research on Cancer, Lyon, France*
- > **The Molecular Tumour Board: a critical infrastructure for delivery of Precision Medicine** | **Júlio Oliveira**, *Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal*

Debate (to be confirmed):

- > **Bettina Ryll**, *Cancer Mission Board member, Uppsala, Sweden*
- > **Susan Galbraith**, *AstraZeneca, Cambridge, UK*
- > **Fátima Cardoso**, *Champalimaud Clinical Center, Lisbon, Portugal*
- > **José Carlos Machado**, *Institute for Investigation and Innovation in Health (i3S), Porto, Portugal*

14:40-16:30 - SESSION 3. INFRASTRUCTURE FOR OUTCOMES RESEARCH

Chair: **Joachim Schuz**, *International Agency for Research on Cancer, Lyon, France*

Presentations:

- > **Outcomes research Infrastructure to support the development of primary prevention** | **Joachim Schüz**, *International Agency for Research on Cancer, Lyon, France*

- > Outcomes research infrastructure to support the development of cancer screening | **Partha Basu**, *International Agency for Research on Cancer, Lyon, France*
- > Outcomes research infrastructure to support the assessment of clinical effectiveness of therapeutic innovations | **Nils Wilking**, *Karolinska Institutet, Stockholm, Sweden*
- > Infrastructure support for cancer specific Health-Related Quality of Life research | **Karen Steindorf**, *National Center for Tumour Diseases and German Cancer Research Center, Heidelberg, Germany*
- > Outcomes research infrastructure for survivorship research | **Françoise Meunier**, *Former head of the European Organisation for Research and Treatment of Cancer, Brussels, Belgium*
- > Health economics as an integrated part of the cancer research continuum for prevention and therapeutics | **Bengt Jönsson**, *Stockholm School of Economics, Stockholm, Sweden*
- > A case study: outcomes implementation and measurement in lung cancer | **Marta Soares**, *Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal*

Debate (to be confirmed):

- > **Jose M. Martin-Moreno**, *University of Valencia, Spain*
- > **Florian Alexandru Nicula**, *Institute of Oncology, Cluj-Napoca, Romania*
- > **Maja Primic-Zakelj**, *Institute of Oncology, Ljubljana, Slovenia & Formerly Head of Epidemiology and Cancer Registry, Ljubljana, Slovenia*

16:30-17:05 - SESSION 4. EU-USA CANCER RESEARCH COOPERATION

Chair: **Michael Baumann**, *German Cancer Research Centre (DKFZ), Heidelberg, Germany*

- > Strategic development of precision cancer medicine in the US | **Richard Schilsky**, *Past President and former Chief Medical Officer, American Society of Clinical Oncology, Alexandria, VA, USA*

17:05-17:15 - CLOSING REMARKS

- > **António Sousa Pereira**, *Rector, University of Porto, Porto, Portugal*
- > **Rui Henrique**, *Chairman of the Board, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal*
- > **Julio E. Celis**, *Chair of the Science Policy Committee of the European Academy of Cancer Sciences (EACS) and Danish Cancer Society Research Centre, Denmark*
- > **Mariya Gabriel**, *European Commissioner for Innovation, Research, Culture, Education & Youth, European Union*
- > **Manuel Heitor**, *Minister for Science, Technology and Higher Education, Portugal*

2021
PORTUGAL.EU

